Wendy Lee, MD, sat down with Ophthalmology Times to discuss a symposium she participated in at Eyecon 2024 focusing on ...

THEY may be the window to your soul, but it turns out your eyes can also be a window to your overall health. While your ...

Amgen announced that Tepezza (teprotumumab [Genetical Recombination]) was approved by Japan's Ministry of Health, Labour and ...

Among patients with autoimmune hyperthyroidism, those who use cannabis were 1.9 times more likely to develop exophthalmos ...

All the time leading up to this and almost all the time since, I've only had one short "active" period of thyroid eye disease (TED). My only noticeable symptom was double vision, but it went away ...

Having dry eyes in the evening or upon waking could be related to prolonged screen time or disrupted sleep quality. Find a ...

(RTTNews) - Amgen (AMGN) said that Japan's Ministry of Health, Labour and Welfare approved TEPEZZA (Teprotumumab) for the treatment of active or high clinical activity score (CAS) Thyroid Eye Disease ...

Amgen yesterday revealed that Tepezza (teprotumumab [genetical recombination]) has been approved for the treatment of active ...

Acelyrin's Lonigutamab offers a competitive edge with subcutaneous administration, higher potency, and lower adverse events.

Topline data were announced from a phase 3 study evaluating veligrotug in patients with active thyroid eye disease.

Clinical studies of the efficacy and safety in patients with mild active thyroid eye disease have not been conducted. Dose and Administration The usual adult dosage is 10 mg/kg as teprotumumab ...